Literature DB >> 7371704

Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.

R A Ahmad, H J Rogers.   

Abstract

A high performance thin layer chromatographic assay for dapsone is described with a minimum level of detection of 20 ng ml-1 which is suitable for the study of dapsone pharmacokinetics in plasma and saliva. 100 mg dapsone was administered orally to seven normal adult volunteers, the mean plasma pharmacokinetic parameters were: alpha = 0.23 h-1; beta = 0.0236 h-1, and t1/2 beta = 30.2 h. Dapsone is also eliminated into the saliva and the t1/2 may be determined via its estimation in saliva. It is 73% bound to plasma protein and the saliva/plasma concentration ratio was found to be 27%. In two subjects the free plasma dapsone concentration was identical to the simultaneous salivary dapsone concentration. Therefore the salivary dapsone concentration is a measure of the free plasma fraction of dapsone. Saliva/plasma dapsone concentration ratios show no time or concentration dependence and little inter-individual variation but are unsuitable for acetylator phenotype determination because monoacetyldapsone is not eliminated in the saliva.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7371704     DOI: 10.1007/bf00562621

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide.

Authors:  R L Galeazzi; L Z Benet; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

2.  Anti-inflammatory actions of dapsone and its related biochemistry.

Authors:  K Williams; R B Capstick; D A Lewis; R Best
Journal:  J Pharm Pharmacol       Date:  1976-07       Impact factor: 3.765

3.  Use of saliva in therapeutic drug monitoring.

Authors:  M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal:  Clin Chem       Date:  1977-02       Impact factor: 8.327

4.  Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites.

Authors:  Z H Israili; S A Cucinell; J Vaught; E Davis; J M Lesser; P G Dayton
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

5.  Hydralazine elimination in man.

Authors:  M M Reidenberg; D Drayer; A L DeMarco; C T Bello
Journal:  Clin Pharmacol Ther       Date:  1973 Nov-Dec       Impact factor: 6.875

6.  Curve fitting by spline and Akima methods: possibility of interpolation error and its suppression.

Authors:  J Fried; S Zietz
Journal:  Phys Med Biol       Date:  1973-07       Impact factor: 3.609

7.  A new analytical procedure for dapsone. Application to blood-level and urinary-excretion studies in normal men.

Authors:  A J Glazko; W A Dill; R G Montalbo; E L Holmes
Journal:  Am J Trop Med Hyg       Date:  1968-05       Impact factor: 2.345

8.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

9.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

10.  Absorption, metabolism and excretion of di(rho-aminophenyl) sulphone (dapsone) and di(rho-aminophenyl) sulphoxide in man.

Authors:  G A Ellard
Journal:  Br J Pharmacol Chemother       Date:  1966-01
View more
  11 in total

1.  The pharmacokinetics of dapsone after oral administration to healthy volunteers.

Authors:  F A Pieters; J Zuidema
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

2.  The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.

Authors:  M J Vandenburg; P Wright; J Holmes; H J Rogers; R A Ahmad
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

3.  Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation.

Authors:  R A Ahmad; H J Rogers; M Vandenburg; P Wright
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of dapsone.

Authors:  J Zuidema; E S Hilbers-Modderman; F W Merkus
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

Review 5.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

6.  N-acetylation phenotyping with dapsone in a mainland Chinese population.

Authors:  Y Horai; H H Zhou; L M Zhang; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

7.  A rapid method for determination of acetylation phenotype using dapsone.

Authors:  P A Philip; M S Roberts; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

8.  Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine.

Authors:  R A Ahmad; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

9.  Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers.

Authors:  G A Breen; J M Brocavich; J V Etzel; V Shah; P Schaefer; S Forlenza
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.